Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daprodustat - GSK

Next Previous
Drug Profile

Daprodustat - GSK

Alternative Names: 1278863; Duvroq; GSK-1278863; GSK-1278863A; Jesduvroq

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Acetic acids; Amides; Anti-ischaemics; Antianaemics; Cyclohexanes; Foot disorder therapies; Ketones; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Anaemia
  • Discontinued Diabetic foot ulcer; Perioperative ischaemia; Peripheral arterial disorders; Tendon injuries

Most Recent Events

  • 17 Mar 2025 GSK completes the phase III ASCEND-P trial in Anaemia (In infants, In children, In adolescents) in Poland, Spain, Japan, South Korea, Italy, France, Belgium, Austria (PO) (EudraCT2021-002013-34) (NCT05682326)
  • 13 Jun 2024 Pharmacodynamics data from a preclinical trial in Anaemia presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 06 Sep 2023 Phase-III clinical trials in Anaemia (In infants, In children, In adolescents) in Poland, Spain, Japan, South Korea, Italy, France, Belgium, Austria (PO) (NCT05682326)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top